A new international study finds that prolonged, intense initial treatment in children with multi-system Langerhans cell histiocytosis (MS-LCH) can achieve survival rates as high as 84 percent - a full 15 percent improvement over the previous clinical trial in this series. The study, LCH-III, is...
A study by a Baylor College of Medicine physician-researcher has shed light on the most effective treatment for adults with Langerhans cell histiocytosis (LCH) in bones. LCH is a disease that can affect the skin, mouth, ears, bones, brain, gastrointestinal system, liver, spleen, or bone marrow...